Literature DB >> 16504704

The use Prometheus FPSA system in the treatment of acute liver failure: preliminary results.

A Skwarek1, M Grodzicki, P Nyckowski, M Kotulski, K Zieniewicz, B Michalowicz, W Patkowski, I Grzelak, A Paczkowska, D Giercuszkiewicz, J Sańko-Resmer, L Paczek, M Krawczyk.   

Abstract

UNLABELLED: The preliminary outcomes of patients with acute liver failure treated with the Prometheus Fractionated Plasma Separation and Absorption (FPSA) system are presented herein. PATIENTS AND METHODS: The procedures were performed in 13 patients (4, intoxication by Amanita phalloides; 4, unknown reason; 3, acetaminophen intoxication; 1, Wilson disease, and 1, liver insufficiency after hemihepatectomy owing to metastases of colon adenocarcinoma). The patients were qualified for the procedure according to the King's College Hospital criteria. The patients' general status was assessed on basic of GCS, UNOS, and the 4-grade encephalopathy classifications. The procedures were performed with the Prometheus 4008H Fresenius Medical Care unit.
RESULTS: The 29 procedures were of mean duration 6.5 hours. There were statistically significant reductions in total bilirubin, ammonia, and aminotransferase levels. In addition, the procedures corrected water, mineral, and carbohydrate disorders. One patient did not require liver transplantation. Seven patients received liver transplants: three patients with positive outcomes; two died due to septicemia within 30 days perioperatively, one died at 6 months after OLT owing to respiratory failure; and one, owing to hemorrhagic diathesis. Four patients did not receive a liver transplant because of lack of a organ, no consent for the surgery, or neoplastic disease with metastases.
CONCLUSIONS: The Prometheus FPSA-System was an effective detoxication method for patients with acute liver failure. The system was useful as a symptomatic treatment before liver transplantation allowing a longer wait for a graft.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504704     DOI: 10.1016/j.transproceed.2005.12.011

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

Review 1.  The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases.

Authors:  Christina Nikokiraki; Adriana Psaraki; Maria G Roubelakis
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

2.  Thermodynamic considerations in solid adsorption of bound solutes for patient support in liver failure.

Authors:  John F Patzer
Journal:  Artif Organs       Date:  2008-07       Impact factor: 3.094

3.  Evaluation of a novel hybrid bioartificial liver based on a multi-layer flat-plate bioreactor.

Authors:  Xiao-Lei Shi; Yue Zhang; Xue-Hui Chu; Bing Han; Jin-Yang Gu; Jiang-Qiang Xiao; Jia-Jun Tan; Zhong-Ze Gu; Hao-Zhen Ren; Xian-Wen Yuan; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 4.  Cell and tissue engineering for liver disease.

Authors:  Sangeeta N Bhatia; Gregory H Underhill; Kenneth S Zaret; Ira J Fox
Journal:  Sci Transl Med       Date:  2014-07-16       Impact factor: 17.956

Review 5.  Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure.

Authors:  Constantine J Karvellas; Noel Gibney; Demetrios Kutsogiannis; Julia Wendon; Vincent G Bain
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.